MX2021015872A - Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1. - Google Patents

Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1.

Info

Publication number
MX2021015872A
MX2021015872A MX2021015872A MX2021015872A MX2021015872A MX 2021015872 A MX2021015872 A MX 2021015872A MX 2021015872 A MX2021015872 A MX 2021015872A MX 2021015872 A MX2021015872 A MX 2021015872A MX 2021015872 A MX2021015872 A MX 2021015872A
Authority
MX
Mexico
Prior art keywords
positive allosteric
allosteric modulator
tetrahydroisoquinoline derivative
substituted tetrahydroisoquinoline
substituted
Prior art date
Application number
MX2021015872A
Other languages
English (en)
Inventor
Anne Valade
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MX2021015872A publication Critical patent/MX2021015872A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a compuestos de acuerdo con la fórmula (I), (ver Fórmula) que son moduladores alostéricos positivos de D1 y, en consecuencia, son beneficiosos como agentes farmacéuticos para el tratamiento de enfermedades en las cuales los receptores D1 juegan un papel.
MX2021015872A 2019-07-01 2020-06-29 Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1. MX2021015872A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19183641 2019-07-01
PCT/EP2020/068181 WO2021001286A1 (en) 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

Publications (1)

Publication Number Publication Date
MX2021015872A true MX2021015872A (es) 2022-02-03

Family

ID=67137842

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015872A MX2021015872A (es) 2019-07-01 2020-06-29 Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1.

Country Status (19)

Country Link
US (1) US20220251064A1 (es)
EP (1) EP3993795A1 (es)
JP (1) JP2022537994A (es)
KR (1) KR20220029687A (es)
CN (1) CN114008032B (es)
AR (1) AR119317A1 (es)
AU (1) AU2020299705A1 (es)
BR (1) BR112021022379A2 (es)
CA (1) CA3139622A1 (es)
CL (1) CL2021002949A1 (es)
CO (1) CO2021017740A2 (es)
EC (1) ECSP22007557A (es)
IL (1) IL289317A (es)
MA (1) MA56445A (es)
MX (1) MX2021015872A (es)
PE (1) PE20220373A1 (es)
SG (1) SG11202112539XA (es)
WO (1) WO2021001286A1 (es)
ZA (1) ZA202109194B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3211578A1 (en) * 2021-03-09 2022-09-15 Kevin Michael BIGLAN Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009009415A (es) 2007-03-01 2009-09-11 Janssen Pharmaceutica Nv Compuestos de tetrahidroisoquinolina como moduladores del receptor h3 de la histamina.
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
CA2963951C (en) 2014-10-08 2023-02-28 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
CN108884050B (zh) * 2016-04-13 2022-07-05 Ucb生物制药私人有限公司 四氢异喹啉衍生物
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Also Published As

Publication number Publication date
CN114008032A (zh) 2022-02-01
EP3993795A1 (en) 2022-05-11
PE20220373A1 (es) 2022-03-16
BR112021022379A2 (pt) 2022-03-08
CA3139622A1 (en) 2021-01-07
ZA202109194B (en) 2023-11-29
WO2021001286A1 (en) 2021-01-07
TW202115009A (zh) 2021-04-16
AU2020299705A1 (en) 2021-12-09
AR119317A1 (es) 2021-12-09
JP2022537994A (ja) 2022-08-31
IL289317A (en) 2022-02-01
SG11202112539XA (en) 2021-12-30
CN114008032B (zh) 2023-11-10
MA56445A (fr) 2022-05-11
ECSP22007557A (es) 2022-02-25
CL2021002949A1 (es) 2022-07-15
KR20220029687A (ko) 2022-03-08
US20220251064A1 (en) 2022-08-11
CO2021017740A2 (es) 2022-01-17

Similar Documents

Publication Publication Date Title
MX2021006421A (es) Anilidas de aminoácidos como moduladores de moléculas pequeñas de interleucinas-17 (il-17).
PH12016500777B1 (en) Compositions and methods for modulating farnesoid x receptors
MX2020007853A (es) Composiciones farmaceuticas para el tratamiento de fibrosis quistica.
PH12018500777A1 (en) Farnesoid x receptor modulators
EA201590118A1 (ru) Производные пирролидина и их применение в качестве модуляторов пути активации комплемента
ZA202109193B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
GEP20207102B (en) Sulfonamides as modulators of sodium channels
EA029089B9 (ru) Модуляторы метил-модифицирующих ферментов, композиции и их применение
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
ECSP088854A (es) Moduladores bencimidazolicos de vr1
MY181959A (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
EA201891377A1 (ru) ПРИМЕНЕНИЕ МОДУЛЯТОРОВ КАНАЛОВ Kv3.1/Kv3.2/Kv3.3 ДЛЯ ЛЕЧЕНИЯ БОЛИ
MX366820B (es) Moduladores de gpr120 del acido biciclo[2.2.2].
EA201992679A1 (ru) N-замещенные индольные производные
MX2020011405A (es) Derivados de bencimidazol como moduladores del receptor gamma huerfano (rory) relacionado con retinoide y usos farmaceuticos de los mismos.
EA201892264A1 (ru) Производные тетрагидроизохинолина
EA201792594A1 (ru) Положительные аллостерические модуляторы мусаринового рецептора м1
EA201692300A1 (ru) Производные карбоксамида
MX2015011375A (es) Moduladores del receptor acoplado a proteina-g 120 (gpr120) de acido biciclo-[2.2.1].
ZA202109194B (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
MX2017009514A (es) Moduladores de los receptores a3 de adenosina.
EA201991728A1 (ru) Модуляторы аденозиновых рецепторов a
MX2023001906A (es) Diarilureas como moduladores alostericos de cannabinoide cb1.
BR112019024708A2 (pt) composições farmacêuticas de liberação prolongada retardada
MX2019014436A (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa.